Xenetic Biosciences Inc. (XBIO) and Immuron Limited (NASDAQ:IMRN) Comparing side by side

Xenetic Biosciences Inc. (NASDAQ:XBIO) and Immuron Limited (NASDAQ:IMRN) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Xenetic Biosciences Inc. 18 0.00 N/A -0.81 0.00
Immuron Limited 6 0.00 N/A -0.68 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 shows us Xenetic Biosciences Inc. and Immuron Limited’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Xenetic Biosciences Inc. 0.00% -62.3% -45.1%
Immuron Limited 0.00% 0% 0%

Institutional & Insider Ownership

Xenetic Biosciences Inc. and Immuron Limited has shares held by institutional investors as follows: 11% and 3.06%. Insiders held 58.2% of Xenetic Biosciences Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Xenetic Biosciences Inc. -10.37% -23.4% -40.46% -54.18% -34.6% -26.22%
Immuron Limited 2% -27.29% -28.09% -43.44% -55.78% -12.24%

For the past year Xenetic Biosciences Inc.’s stock price has bigger decline than Immuron Limited.


On 4 of the 6 factors Immuron Limited beats Xenetic Biosciences Inc.

Xenetic Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, research, and development of biologic drugs and orphan oncology therapeutics. Its lead proprietary technology is PolyXen, a platform technology for biologic drug delivery. The companyÂ’s lead drug candidate is XBIO-101, a small-molecule immunomodulator and interferon inducer for the treatment of progesterone receptor negative endometrial cancer and triple negative breast cancer. It also develops OncoHist for the treatment of acute myeloid leukemia. The company has a research, development, license, and supply agreement with Shire plc to develop SHP656, a polysialylated recombinant (rFVIII) protein to treat hemophilia; and a collaborative research and development license agreement with PJSC Pharmsynthez to develop, commercialize and market PulmoXen for the treatment of cystic fibrosis, as well as Xemys for the treatment of multiple sclerosis. Xenetic Biosciences, Inc. is headquartered in Lexington, Massachusetts.

Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle. The company markets and sells Travelan for the prevention of travellersÂ’ diarrhea. Its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. The company also has other preclinical immunotherapy pipeline products targeting immune-related diseases. Immuron Limited has a research and development collaboration agreement with the Walter Reed Army Institute of Research (WRAIR) for the development of a Shigella vaccine; and Naval Medical Research Center for the testing of Travelan in cell lines of campylobacter and enterotoxigenic escherichia coli. The company was founded in 1994 and is based in Blackburn North, Australia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.